Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 8, 2026

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

1.3K

Radiosensitization by gemcitabine.

T S Lawrence1, A Eisbruch, C J McGinn

  • 1Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, USA.

Oncology (Williston Park, N.Y.)
|November 7, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diffusion MRI correlation with p16 status and prediction for tumor progression in locally advanced head and neck cancer.

Frontiers in oncology·2024
Same author

Response to Kibe Y et al. "Methodological concerns for investigating the effects of midtreatment break of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC)".

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2020
Same author

A mid-treatment break and reassessment maintains tumor control and reduces toxicity in patients with hepatocellular carcinoma treated with stereotactic body radiation therapy.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2019
Same author

Treatment data and technical process challenges for practical big data efforts in radiation oncology.

Medical physics·2018
Same author

Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Characteristics of Successful and Probationary Football Officials.

The Physician and sportsmedicine·2016
Same journal

Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

Oncology (Williston Park, N.Y.)·2026
Same journal

Access to Care and the Affordable Care Act: Why Do Problems Exist 15 Years Later?

Oncology (Williston Park, N.Y.)·2026
Same journal

Synchronous Endometrial and Ovarian Cancers: A Case Study and Literature Review.

Oncology (Williston Park, N.Y.)·2026
Same journal

Perceived Social Support, Anxiety, and Depression Among Women With Breast Cancer.

Oncology (Williston Park, N.Y.)·2026
Same journal

Before Certainty.

Oncology (Williston Park, N.Y.)·2026
Same journal

Adult T-Cell Leukemia/Lymphoma and Epstein-Barr Virus-Positive DLBCL: A Rare Concomitant Association.

Oncology (Williston Park, N.Y.)·2026
See all related articles

Gemcitabine enhances radiation therapy effectiveness by sensitizing tumor cells, but careful dosing is needed to avoid excessive normal tissue toxicity in cancer patients.

Area of Science:

  • Oncology
  • Radiation Oncology
  • Cancer Therapeutics

Background:

  • Gemcitabine is recognized as a potent radiosensitizer in preclinical and clinical settings.
  • It effectively sensitizes various rodent and human tumor cells in vitro.
  • Maximum radiosensitization is linked to S-phase redistribution and deoxyadenosine triphosphate pool depletion.

Purpose of the Study:

  • To investigate the efficacy and toxicity of gemcitabine as a radiosensitizer in cancer treatment.
  • To explore the mechanism of gemcitabine-induced radiosensitization, potentially involving apoptosis.
  • To optimize gemcitabine dosing in combination with radiation therapy for head and neck and pancreatic cancers.

Main Methods:

  • Laboratory studies involving cell cultures to assess radiosensitization.

More Related Videos

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors
04:53

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors

Published on: August 25, 2022

2.2K
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K

Related Experiment Videos

Last Updated: Feb 8, 2026

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine
05:39

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

1.3K
Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors
04:53

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors

Published on: August 25, 2022

2.2K
Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

7.5K
  • Clinical dose-escalation trials in patients with unresectable head and neck and pancreatic cancers.
  • Preclinical animal models to evaluate therapeutic index and mitigate toxicity.

    • Main Results:

    • Gemcitabine significantly potentiates treatment toxicity in head and neck cancer patients, even at sub-maximal doses.
    • Normal tissue sensitization appears less pronounced in pancreatic cancer treatment compared to head and neck cancer.
    • Evidence suggests gemcitabine may lower the threshold for radiation-induced apoptosis.

    Conclusions:

    • Gemcitabine shows promise as a radiation sensitizer in oncology.
    • Cautious development is essential to manage and avoid excessive normal tissue toxicity.
    • Further research using animal models is warranted to improve the therapeutic index of gemcitabine-based radiation therapy.